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In later stages of retinal degenerative diseases such as age-related macular degeneration (AMD) 
and retinitis pigmentosa stem cell therapy can be the only viable treatment option due to the loss 
of photoreceptor and RPE cells. Differentiation of embryonic stem cells (ESCs) towards the 
desired lineage explicitly requires a microenvironment that mimics the natural tissue that it is 
intended to regenerate. Developing a planar 3D retinal graft derived from ESCs can be transplanted 
to treat various retinal degeneration diseases. Our aim was to explore the differentiation and growth 
of ESCs on a gelatinous scaffold in order to transplant into a retinitis pigmentosa mouse model 
(RD10). Our aim was to evaluate the transplanted graft for host inflammatory response, stem cell 
integration, cell survival, and tumorigenesis. The transplanted graft was also compared to injection 
of a homogenous photoreceptor cell population into the subretinal space of the RD10 mouse 
model. A biocompatible gelatinous scaffold was developed in order to support the differentiation 
of a multilayered retinal structure. ESCs were seeded onto the scaffold for proliferation and 
differentiation in the vicinity of retinal pigment epithelium cells. Cultures were analyzed for 
differentiation by qRT-PCR and immunofluorescence confocal microscopy. The graft was 
transplanted into the subretinal space to examine biocompatibility and retinal progenitor cell 
integration into the native mouse retina.  ESCs migrated through the 60µm thickness of the scaffold 
and differentiated into the retinal progenitor cells as evidenced by qRT-PCR and 
immunohistochesmistry.  In-vivo testing analyzed on 1st, 3rd and 6th week showed scaffold 
degradation by the 6th week. The gelatinous scaffold supported the differentiation of ESCs to RPCs 
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Retinal Degeneration and future Intervention Methods 
Patients with retinal degenerative diseases have many pathways which are negatively affected in 
photoreceptor cells. Pathways such as phototransduction, lipid metabolism, RNA splicing, inner 
and outer segment formation of photoreceptor cells, vesicle trafficking and protein folding can be 
malfunctioning (1). The retinal pigment epithelium (RPE) underlying the photoreceptor layer, 
responsible for nourishing the retina, can have mutations in phagocytosis, light sensitive rhodopsin 
regeneration, and ion trafficking causing photoreceptor dysfunction and ultimately death of these 
cells (2,3). 
Pharmacotherapy or neuroprotective agents can be used in early stages of the disease when the 
photoreceptors are still viable. Gene therapy can be used when there is a single genetic mutation 
Figure 1- Strategies used to treat retinal degeneration at different time points. Gene therapy is 
used at earlier stages when the photoreceptors are intact. Pharmacotherapy and neuroprotective 
strategies are suitable in ongoing photoreceptor cell degeneration. Stem cell therapy, 
optogenetic therapy, and retinal prostheses are needed to restore vision during the later stages 




that can be corrected using the CRISPR/Cas9 system or AAV vector transfection containing the 
corrected gene insert (4,5). However, in a heterogeneous retinal degenerative disease when there 
is not a single genetic mutation and in later stages of the disease when the photoreceptor cells are 
not viable, retinal stem cell replacement can be the only solution to vision restoration or 
preservation. 
Retinal degenerative diseases such as age-related macular degeneration (AMD), Stargardt disease, 
and retinitis pigmentosa, are phenotypically diverse but can be treated with stem cell therapy (6,7). 
In the population above the age of 55, AMD is the leading cause of blindness worldwide. AMD 
affects 1.75 million people in the USA alone and will affect nearly 196 million people worldwide 
by 2020 (8).  
Retinitis pigmentosa (RP) encompasses a heterogenous group of progressive retinal degenerative 
disorders with a worldwide prevalence of 1 in 3500–5000 individuals (9). Patients with RP 
typically present in later stages of the disease given that their central vision remains intact for a 
long time. These and many other currently untreatable retinal conditions are the subject of many 
clinical trials using embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) to 
treat these underlying conditions (10,11) 
During retinogenesis, ESCs undergo a stepwise developmental process through primitive eye field 







Retinitis Pigmentosa and retinal stem cell Transplantation
  
 
Retinitis pigmentosa (RP) is an inherited disease which claims a person’s vision over decades. 
There are still many unknown genetic mutations that can cause RP. It is difficult to develop a 
single specific gene therapy as patients afflicted with RP have an extensive disease causing genetic 
heterogeneity (13). Loss of functional proteins leads to disruption of normal photoreceptor cell 
structure causing cell death and irreversible blindness. As one example, Lamba et al. (14), 
transplanted retinal progenitor cell (RPC) suspensions into normal mice and mice with 
photoreceptor genetic defect.  This experiment showed that the RPC could migrate and integrate 
into the various layers of the retina, but only if they were injected before the retinal degeneration 
began. A careful reading of the report reveals that transplanted RPC slowed the progression of the 
disease, but could not reverse the degeneration that had already occurred (13). The RPC graft 
suspensions fail when they are introduced into a diseased environment.  By engineering the RPCs 
a b 
Figure 2- Panel A: fundus photograph of a patient suffering from retinitis pigmentosa. In 
the areas with increased dark pigmentation photoreceptor death has occurred as the pigment 






into a flat tissue in which cell-cell interactions are already established, or by developing a 
homogenous photoreceptor cell population, the graft might survive and integrate with the remnants 
of the host tissue to restore lost vision. 
 
Planar retinal graft development 
 
The problem confronting the field is that the more mature assemblies of differentiated RPC cannot 
be transplanted for two reasons: The assemblies of retinal-like cells do not survive dissociation to 
single cells and injection into the subretinal space. The geometry of the cell assemblies is not 
amenable to transplantation.  Depending on the protocol the cells form rosettes on a culture dish 
or neurospheres in suspension culture.  The rosettes and neurospheres are of small diameter and 
would have to be converted to flat sheets in order to interact with the host retina and RPE.  
Accordingly, the only successful transplantation experiments involve suspensions of immature 
a b 
Figure 3- The illustration depicts the layered retinal anatomy and injection of stem cells 
into the subretinal space of the mouse eye using a trans-scleral approach given the lens is 
bigger in mice compared to human eyes. Panel a is adapted from 4a. Panel b courtesy of 





cells in the earliest stages of retinal degeneration. Later investigators achieved some success in late 
stage disease using mouse models of retinal degeneration. Rod precursors were purified and the 
suspension was injected into the subretinal space after the photoreceptor layer degenerated.  
Success depended on the disease model that was used (15,16). Several labs have cultured RPC in 
sheets, but the scaffolds used would block interactions with either the host retina or the RPE 
(17,18). With designing a biocompatible scaffold that would foster differentiation of H9 
embryonic stem cells (ESCs) it is possible to develop planar retinal structures. 
Electrospun fibers of ε-polycaprolactone was tested in the Rizzolo lab in prior years. It did foster 
ESC differentiation into RPCs. However, it did not allow for full thickness migration (120 µm) of 
the cells through the scaffold. This prompted the Rizzolo lab to develop a porous scaffold made 
with hyaluronic acid, chondroitin sulfate and gelatin which closely resembles the retinal basement 
membrane composition. The gelatinous scaffold was used to differentiate the RPCs in a planar 
structure above the retinal pigment epithelium (RPE) layer. The differentiation of ESCs in the 
vicinity of RPE mimics the in vivo environment where photoreceptors are naturally developing. 
This contact with the RPE can help guide the differentiation of ESCs into photoreceptors in vitro.  
There have been many established tissue culture methods that are used to differentiate RPCs into 
different retinal cells in vitro. A converging body of data has showed the ability of human 
embryonic stem cells (hESC) and induced pluripotent cells (hiPSC) to differentiate into neural 
retinal lineages and finally become photoreceptors and interneurons (19). However, to develop 
functional photoreceptor outer segments the RPE is required.  It is unknown if co-culture with RPE 
would induce synapse formation between the photoreceptors and interneurons to create a light-
sensitive tissue. I will be using the RPE/RPC coculture method developed by the Rizzolo lab for 





Ongoing retinal stem cell transplantation clinical trials 
ESC derived photoreceptor transplantation trials are still being completed. However, ESC derived 
RPE stem cell transplantation has been done. A landmark study of ESC transplantation done by 
Schwartz et al. showed that 5x104 ESC-derived RPE cells can successfully be transplanted into 
the eye of patients with age related macular degeneration (AMD) and Stargardt’s macular 
dystrophy.  Four years post transplantation, these Phase 1/2 clinical trials did not show signs of 
rejection, ectopic tissue or tumor formation, or hyperproliferation. (10).  The ESC-derived RPE 
transplantation was done in 18 patients which confirmed long- term safety and graft survival. 
Patients tolerated the graft well and the adverse effects were mainly limited to the surgical 
procedure and oral immunosuppressive regimen. Even though the eye is considered to be an 
immune privileged organ the patients were on an oral immunosuppressive regimen given the cells 
were derived from ESC (20). At the end of the trial, there was minimal improvement in best-
corrected visual acuity and quality-of-life measures. More tests such as microperimetry, auto 
fluorescence imaging, optical coherence tomography scanning, and multifocal electroretingram 
can be done to establish visual function (21). In order to reduce the need for oral 
immunosuppressive therapy, iPSC derived RPE can be used if the cells are obtained from the 
patient. 
Preliminary mouse studies have grafted human iPSC-derived RPE cells into the subretinal space 
of mouse eyes. This study found that human iPSC-derived RPE cells restored some retinal function 
assessed by electroretinography in a mouse possessing the mutation in a gene known to be 
responsible for certain types of retinitis pigmentosa (RP) (22). 




This protein is essential in converting all-trans retinol to 11-cis retinal during photoreceptor 
phototransduction and visual pigment regeneration (23).  
 
 
To test retinitis pigmentosa (RP) reversal in vivo, I transplanted our engineered retina into RD10 
mice, which has a PDE6b gene knockout. PDE6b KO causes degeneration of rod and cone 
photoreceptors and is also a gene that is linked to RP in humans and some cases of Leber congenital 
amaurosis (25). Notably, the RD10 mouse’s phenotype causes the photoreceptor layer to 
degenerate from full thickness starting at 16 days until photoreceptors are nearly absent after 35 
days after in the central retina. 
 
Figure 4- This panel demonstrates the RD10 mouse retinal histology over time. The outer 
nuclear layer (ONL) thinning, which corresponds to photoreceptor degeneration, is 
significant by day 30. Arrows are depicting actively dying photoreceptors. Figure adapted 






Statement of Purpose 
Aim 1. Develop a planar retinal graft on a gelatinous scaffold for in vivo transplantation of a 
homogenous RPC population or purified rod precursors for subretinal injection. 
 I hypothesize that development of a multilayered planar retinal graft will enhance the 
integration of RPCs into the injured photoreceptor layer and further differentiation into the 
photoreceptor lineage in vivo. Moreover, I want to compare the transplantation of the RPC/GCH 
graft to the injection of a homogenous photoreceptor cell suspension in the subretinal space. 
Aim 2. Evaluate the side effects of RPC graft/scaffold transplantation such as tumergenicity, 
uveitis, retinal edema, inflammatory response and retinal scaring. 
I hypothesize that since the scaffold is mostly made of gelatin, hyaluronic acid, and chondroitin 
sulfate and roughly resembles the matrix of the retina that the inflammatory response will be 
minimal and the scaffold can be degraded in vivo. Also the since the scaffold is implanted in the 
subretinal space, which is immune privileged, inflammatory response is minimum. 
Aim 3. Transplantation of in-vitro differentiated RPC into a retinitis pigmentosa mouse models at 
the intermediate and late stages of disease. 
I hypothesize that RPCs can migrate towards the layer of injury and will integrate in the 
photoreceptor layer in the retinitis pigmentosa mouse model given the photoreceptor layer has 







Materials and Methods 
C57/BL6 mice and RD10 mice were used at P30. All experiments were done in accordance to 
ARVO statement for the use of animal in ophthalmic and vision research. Gelatin powder was 
purchased from J.T.Baker, New Jersey (USA). Chondroitin sulfate, 90+% and hyaluronic acid was 
obtained from Alfa Aesar, MA (USA). Ammonium persulfate by fisher scientifics, New Jersey 
(USA). N,N,N',N'-Tetramethylethylenediamine, Tri-Buffer-saline with 1% tween 20, Phosphate 
buffer saline (PBS) 1X , pH 7.4 containing 1.4M NaCl, 0.1M phosphate (pH 7.4) and 0.03M KCl 
were all purchased from American BIO, MA (USA). Glutaraldehyde, 50% Ameresco, Ohio 
(USA). Milli-Q-grade water was used in all experiments except for gene expression in which 
nuclease free-water from Bio-rad. i-Script cDNA synthesis kit, iTaqtm Universal SYBRGreen 
Supermix and PCR plates were purchased from Bio-rad, Hercules (USA). All the solvents used 
here without any further purification were purchased from Sigma-Aldrich. 
 
Preparation of 3D scaffold 
Different combination of polymers was used to fabricate the gelatin-chondroitin sulfate-hyaluronic 
acid (GCH) scaffold. 250mg of gelatin, 125mg of chondroitin sulfate and 250mg of hyaluronic 
acid were dissolved in water. 50 µl of glutaraldehyde cross-linker with reaction initiator 
ammonium-persulphate and redox catalyst N,N,N′,N′-tetramethylethylenediamine (TEMED) 
catalyst, were added to the dissolved solution. Polymer solution was frozen at -20 °C for 18 hrs 
and vacuum dried using lyophilizer to produce a solid 3D scaffold. Scaffolds which were 






Human Embryonic stem cells (H9) culture maintenance and differentiation 
Undifferentiated H9 human embryonic stem cells were obtained from the Yale stem cell center. 
Cells were cultured on 1% matrigel coated plates and maintained in mTeSR-1 media. Media was 
changed every 2 days and colonies were regularly scraped under a sterile microscope to remove 
spontaneously differentiating cells. For passaging, colonies were lifted by incubating with 1U/ml 
dispase for 30 min at 37˚c, triturated and washed with DMEM/F-12 nutrient media and plated onto 
newly 1% matrigel-coated dishes.  
For the RPC differentiation process, H9 cells were treated with blebbestatin following the dispase 
step in order to make embryoid bodies (EBs). EBs were cultured in mTeSR-1 at D0. Neural 
induction medium (NIM) containing B27 was added the next day (D1) in a ratio of 1: 3 with 
mTeSR-1. On D2 the concentration of NIM increased to 1:1 with mTeSR-1 and on D3 and 
onwards EBs were cultured in 100% NIM. On D7 the floating EBs were seeded on matrigel coated 
6 well plates and continued to be cultured in NIM until D20. The retinal progenitor cells (RPC) 
were selected and manually dissected out from the plates for further experimentation.  
 
EBs on GCH scaffold seeding for retinal cup differentiation 
EBs formed using H9 were seeded onto GCH scaffold on D20. Scaffolds were sterilized overnight 
with 70% ethanol, washed three times with PBS, then treated with pen-strep for 30 mins and 
soaked in NIM overnight. 6-8 EBs were seeded on the scaffold the following day. Media was 





Immunofluorescence Confocal microscopy 
from D20 onwards, each week seeded scaffolds were collected to observe for cellular migration 
and differentiation using confocal microscopy. Scaffolds were fixed in 4% paraformaldehyde for 
5 mins following wash with cold PBS. Scaffold was placed in OCT fluid and cryotome sectioned 
and placed on glass slides. Sectioned H9-GCH scaffolds were permeabilized with 0.1 Triton-X for 
60 mins. 10% donkey serum containing 0.1% Triton-X solution in PBS was used to block the 
samples for 1 hr.  Next, the sections were incubated overnight with primary antibodies (listed in 
table 2). The slides were washed three times with PBS and blocked again for 1 hr with 10% donkey 
serum in order to reduce background fluorescence before incubation with secondary antibodies 
conjugated with Cy2, Cy3, or Cy5 (Jackson ImmunoResearch Laboratories, West Grove, PA). 
DAPI (4,6-diamidino-2-phenylindole) was used to label the nucleus. Before mounting the slides, 
sections were washed three times with PBS  and fluorescence images were captured with an LSM 
410 spinning-disc confocal microscope and processed using Zen software (Carl Zeiss, Inc, 
Thornwood, NY). Images used are representative of 3 or more experiments. 
 
Electron Microscopy 
EB seeded scaffolds were fixed in 4% paraformaldehyde. Further fixation was done by immersing 
the tissue in 1 % osmium tetroxide for 90 min. Samples were then dehydrated with a graded series 
of ethanol (50–100 %) baths, cleared in propylene oxide, and embedded in epoxy resin. Ultrathin 
sections were cut with an ultramicrotome and stained with uranyl acetate and lead citrate. Stained 





Quantitative Real-time RT-PCR 
Total RNA was extracted using TRIzol reagent (Invitrogen, Paisley) according to manufacturer’s 
instructions. cDNA was reverse transcribed using 2µg of total RNA using QuantiTect Reverse 
Transcription kit (BioRad). Quantitative reverse transcription polymerase chain reaction qRT-PCR 
was synthesized using iTaqSYBR Green (BioRad) and RNA primers generated at Keck 
Oligonucleotide synthesis facility (Yale University). Following positive expression, samples were 
further tested using customized PCR array for 48 genes specific to early eye field, neural retinal 
development, ganglion cells, terminal differentiation of photoreceptors, interneurons and retinal 
pigment epithelium lineage. Relative mRNA expression was normalized with housekeeping genes 
(GAPDH and Actin) and calculated using 2-∆∆Ct method. 
 
FACS sorting 
Differentiating EBs were transfected with the AAV vector carrying the rhodopsin promoter 
upstreams of a Tdtomato sequence, which is a red fluorescent protein, 48 hours prior to flow 
cytometric cell sorting (FACS).  EBs were dissociated with 0.25% trypsin for 15 min and Serum 
free media was added to inactivate the trypsin. Cells were spun down at 1000 rpm and strained to 
obtain a single cell suspension. Analysis was performed using the FACS Calibur system (BD 
Biosciences). 
 
AAV virus preparation 
293FT cell line was maintained with DMEM and 10% FBS and passaged 1:4 every 2 days. The 




transfection (more than 70% confluent). For every 5x150mm culture dish the vector mix was 
prepared with 30 µg AAV vector; AAV rep/cap 50 µg;  adenol helper 60 µg.  The plasmid is mixed 
with 600 µl PEI (1µg/µl) to DNA mixture, vortexed and incubated for 25 min at room temperature. 
120µl is added to each plate and cells harvested 48-72 hours post transfection. Collect cells using 
centrifugation at 1000g for 10 mins. Cell pellet was resuspended in 6 ml lysis buffer (150 mM 
NaCl, 20 mM Tris-HCl pH 8.0).  Cells were lysed using subsequent incubation in dry ice/ethanol 
mixture and 55 C water bath. 250U/Benzonase was added and incubated at 37C for 1 hour while 
vortexing every 15 mins. Cell lysates are centrifuged at 4000 rpm for 30 min and supernatant is 
filtered with a 0.45um syringe filter. The HiTrap heparin columns are setup with a 10 ml syringe 
and flow is kept below 1ml/mins. The column is equilibrated with 10 ml lysis buffer (150Mm 
NaCl, 20Mm Tris-HCl Ph8.0). The viral solution is passed through the column slowly. The column 
is washed with 3 ml 200Mm NaCl, 20Mm Tris-HCl Ph8.0, and 3ml 300Mm NaCl, 20Mm Tris-
HCl Ph8.0 respectively. The virus is eluded with 1.5ml 400Mm NaCl, 20Mm Tris-HCl Ph8.0 and 
concentrated with Amico ultra-4 centrifugal filter units, and washed the collection with DPBS. 
Finally, aliquoted the concentrated virus and stored in -80C. 
 
Animal experiment 
All animal experiments were performed in accordance to the guidelines set and approved by 
Institutional animal care and use committee (IACUC) at Yale University, New Haven, CT. A total 
of two breeding pairs were required to complete this experiment. This pair was used for breeding 
and pups obtained were used for the implantation study. Wild-type and rd10 mice at post-natal day 
30 were used for transplantation and following the completion of experiment mice were euthanized 





Wild-type and RD10 mice implantation  
For transplantation of GCH scaffold alone or scaffold with differentiated retinal cup tissue, the 
scaffold grafts were cut into 0.5 cm dimension and kept in PBS solution. Mice were anesthetized 
by intramuscular injection of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg). A small 
scleral hole was made after conjunctival incision and a local retinal detachment was induced by 
PBS injection.  Subsequently, the scleral incision was enlarged. The small piece of scaffold was 
carefully inserted into the dorsal quadrants of the host retinas. After transplantation, the mice were 
transferred into a dark room for 1-2 days, and then maintained in regular animal facility. 
 
Statistical analysis 
All data presented in this manuscript is shown as the mean + standard deviation (SD) unless 
otherwise indicated. All experiments presented here were completed in biological and technical 
triplicates. The data from the experimental sets were compared with controls and statistical 











Retinal Progenitor Cell Differentiation on GCH scaffold 
  
 
The qRT-PCR analysis showed an increase in the expression of neural and early eye field genes 
of neurospheres on the GCH scaffold from D10. LHX2 shows a 6-fold increase on D24 compared 
to D0. On further testing at D10 and D24, PAX6 expression increased two-fold in comparison to 
D10. RAX and LHX2 increased 2-fold (Fig. 5) indicating the EBs on GCH scaffold were 
differentiating into RPCs. H9 cultured on GCH shows upregulation of important eye field 
transcription factors (RAX, SIX3 and OTX2), photoreceptor genes as evident on Fig. 5. 
Immunofluorescence and confocal microscopy of RPCs also shows the upregulation of OTX2, 





Figure 5- qRT-PCR was done for monitoring neural retinal maturation on the gelatin scaffold. 
Dashed Line: 2X increase vs Day 0. qRT-PCR results are averaged from n=3 separate 





D21 which are early eye field genes (Fig. 6). The expression of these markers was comparable to 
floating EB cultures which were used as a control. 
 
 
Retinal Progenitor Cell interaction with GCH Scaffold 
The final GCH fabrication product resulted in a homogenous scaffold with pore sizes ranging from 
150-190 µm (Fig. 7 A, B). H9-GCH interaction was confirmed using bright-field and scanning 
electron microscope. EBs adhered to the surface of the scaffold (Fig. 7D) and maintained the EB 
morphology with a slightly polarized appearance, and some EBs contained the pigmented RPE 
which is consistent with differentiation towards a self-organizing neuro-epithelial lineage (Fig 
7D). 2 weeks after the EBs were seeded onto the GCH scaffold, DAPI staining was done to assess 
RX MERGE 
Day 21 







Figure 6- Confocal microscopic imaging of H9 differentiation in vitro, shows stepwise 






cellular migration within the scaffold. Confocal microscopy revealed that H9 cells attached, 




RPC differentiation on GCH scaffold with RPE co-culture 
RPCs differentiating on the GCH scaffold were placed on RPE that was cultured on transwell 
filters at D20. The differentiation process continued in proximity to the RPE mimicking in vivo 
conditions. Samples were taken on D90 and immunofluorescence showed a discrete separation 
between recoverin positive cells and LHX2 positive cells as seen in Fig. 8. There was 7-8 rows of 
recoverin positive cells adjacent to the RPE layer which is the location of photoreceptor 






Figure 7- A) Scanning electron microscopy (SEM) image showing macroporous structure 
of the scaffold in 3D, B) and 2D view, (scale bars 1.00 mm and 500µm respectively) C) 
Human embryonic stem cells (H9) seeded onto gelatin scaffold D20 (scale bar 100µm). D) 
ESCs completely infiltrate two weeks after scaffold seeding on BF microscopy. E) ESCs 
migrate through the scaffold thickness (3D view) on confocal imaging. Scale bars 20µm. 







Biocompatibility of RPC/GCH transplantation in wild type mice 
To investigate the in-vivo response to RPC-GCH, the scaffold was implanted in the subretinal 
space of wild type and RD10 mice. Three weeks post transplantation, the RPC-GCH scaffold 
biocompatibility and host inflammatory response was evaluated by IL-6 detection levels in the 
tissue. IL-6 staining was found to be minimal at the site of implantation and around the scaffold in 
both wild-type and RD10 mice (Fig. 9). In wild-type mice transplanted with RPC-GCH, some IL-
6 positive staining was found in and around the area of the choroid which is where IL-6 positive 
Figure 8- The upper panel Represents confocal imaging of H9 cells on the GCH scaffold 
expressing early eye field proteins at D40 (scale bar 20µm).  The lower panel demonstrates 
ESC differentiation in proximity to RPE cells at D90 (scale bar 50µm).  Besides migrating 
into the scaffold, cells proliferate as broad flat clusters on the scaffold and recoverin positive 
cells (green) segregate from LHX2 positive (red) cells. The recoverin positive cells matured 






cells are physiologically present (Fig. 9). However, minimal IL-6 positive cells could be seen at 
the site of implant (Fig. 9). There was minimal host inflammatory response to the transplanted 
scaffold. Most of the scaffold was degraded 6 weeks post transplantation (figure not shown). 
  
  
Migration of transplanted RPC on GCH into host retina 
Immunohistochemistry examination of the RPC-GCH implant in the sub-retinal space of wild type 
mice 6 weeks after implantation shows minimal inflammation and migration of human antigen 
positive cells (TRA-1-85) into other retinal layers of the mice (Fig 10). The TRA-1-85 positive 
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 Figure 9- Confocal image of wild type retina 3 weeks post implantation of RPC on GCH 
scaffold. IL-6, a major inflammatory marker, was used to demonstrate host response to scaffold. 
In both panels there is minimal expression of IL-6 noted suggesting the biocompatible nature 
of the fabricated scaffold. IL-6 is seen in the choroid layer in RD10 panel where it is usually 





that failed to be removed by saline perfusion post euthanasia. In wild type mice, migration is 
minimal unless ONL is diseased or injured. TRA-1-85 positive cells were found within the 
transplanted scaffold showing that the RPCs are viable within the GCH scaffold after 
transplantation.  
 
6 weeks post transplantation of GCH/Scaffold in RD10 mice showed the scaffold had been 
resorbed. However, RPCs were seen to migrate and adhere to the host retina, adding an extra layer 
of cells in the outer nuclear layer (Fig 11). In the ONL there is a layer of TRA1-85 positive cells 
adjacent to a row of recoverin positive cells. TRA-1-85 positive cells were seen to extend their 
cellular processes and migrate deeper into the ONL layer (Fig. 11) indicating that the implanted 
RPC were able to survive transplantation stress, and migrate into the degenerating photoreceptor 
DAPI TRA1-85 RCVR MERGE 
MERGE TRA1-85 TUJ1 
GCL GCL GCL GCL 
ONL 
Figure 10- RPC/GCH scaffold implants in WT mouse 3 weeks post transplantation. The cells 
within the scaffold are positive for human antigen TRA1-85, which shows that mouse cells 
did not invade the scaffold in the subretinal space. Some TRA1-85 positive cells show 
vasculature pattern in the different layers. RPCs do not migrate when there is not a layer of 





layers. To further confirm cellular migration and attachment of RPC into the ONL layer, samples 
were co-stained with recoverin and TRA-1-85 showing a distinct layer of TRA-1-85 positive cells 




















Figure 11- Confocal images the 6th week post implantation. TRA-1-85 (green), recoverin (red) 
and DAPI (blue) cells were found to integrate with the host photoreceptor layer. Recoverin 
staining was performed to confirm the retina orientation. The panel shows TRA-1-85 positive 
cells at site of implant.  The transplanted cells do not express recoverin. At 6 weeks there is 
clear attachment of human antigen positive cells at the site of implantation both at the ONL and 
RPE layers. Scaffold degraded within the 6th week of implantation allowing migration and 





FACS Sorting of Rho + transfected RPCs and subretinal injection in RD10 mice 
Some cells were lost in the process of developing a single cell suspension for FACS given the 
longer exposure to trypsin in order to break up the neurosphere.  20% (2x 10^5 cells) of the RPCs 
were expressing rhodopsin, which is expressed in photoreceptors (Fig. 12).    
 
50,000 cells were injected in one eye of the RD10 mouse. Ku-80 Immunofluorescence, which is 
an antibody marking human antigens, shows the presence of a homogenous photoreceptor 
population in the subretinal space 3 weeks post injection. The cells were viable and intact through 
A 
B 
Figure 12- FACS sorting neurospheres transfected with Td/tomato Rho+ AAV. Photoreceptors 
generally differentiate in the periphery which will express rhodopsin at D50. Panel A shows 
rhodopsin positive cells in the periphery. Panel B demonstrates a distinct population of Rho+ 





the injection process. There was also minimal inflammatory response, given the minimal IL-6 was 




Methods of cellular delivery and survival rate for transplantation has been a technical challenge in 











RPE RPE RPE 
RPE RPE 







Figure 13- Subretinal injection of FACS sorted Rho+ cells in the subretinal space of RD10 
mouse at P30. Confocal images are 3 weeks post-injection. Ku80 is an antibody against 
human antigens. The host cells express recoverin while the injected cells are only Ku-80+. 
IL-6 staining shows minimal inflammatory response in the lower panel. The layer labeled 





cell delivery given current stem cell differentiation protocols result in spherical eye cup structures 
(26). The gelatin-chondroitin sulfate-hyaluronic acid scaffold approximates the retinal 
extracellular composition (27). Gelatin was substituted for collagen, because it is less 
immunogenic than the collagen from which it is derived (28).  I have shown that the H9 ESCs 
differentiate readily on the GCH scaffold compared to the control floating embryoid body cultures. 
Early eye field genes such as RAX, LHX2, PAX6, and OTX2 are upregulated as evident by qRT-
PCR results, immunofluorescence and confocal microscopy.  The ESCs migrate through the 60µm 
thickness of the scaffold given the interconnected scaffold pore morphology constructed through 
rapid freezing and drying using a lyophilizer. Since EB’s are large cell clusters, it is difficult for 
most clusters to achieve complete migration in a 3D structure. However, the macroporous 
interconnected pores of GCH showed the possibility of attaining 3D cellular growth.  The GCH 
scaffold was superior in supporting RPC formation and ESC differentiation in comparison to PCL 
scaffolds previously studied in the Rizzolo lab. ESCs were mostly aggregated on the surface of the 
PCL scaffold given the scaffold did not have the porous structure as the GCH scaffold. Currently, 
the members of the Rizzolo lab have found that GCH coating with laminin 521 further enhances 
RPC attachment, migration and differentiation. 
The RPC/RPE coculture experimental samples clearly formed a planar retinal structure with 
recoverin positive cells differentiating adjacent to the RPE layer. These samples were fixed for 
immunofluorescence on D90 of the differentiation protocol. These samples were not used for 
transplantation studies given the scaffold was partially degraded in culture and did not have the 
mechanical stability to be used in animal studies. The scaffold partially degrades when is placed 




The scaffold causes minimal host inflammatory response when transplanted in both wild type and 
RD10 mice, as there is minimal IL-6 detected on immunofluorescence and there is no retinitis seen 
in mice post transplantation. There is no increase in IBA-1 or IL-6 positive cells at the site of 
implant or within the vicinity of the scaffold. Few IL-6 positive cells were detected in the 
photoreceptor layer in both wild type and RD10 mice at the 1st week post transplantation could be 
due to surgical procedure or host response to the graft. However, in the later stages absences of 
both types of cells indicates the graft was well tolerated by the host and does not cause a major 
inflammatory response.  
The GCH scaffold is mostly degraded at 6 weeks post transplantation, however there is a retinal 
detachment at the site of transplantation when the scaffold is degraded. The retinal detachment is 
caused by the volume of the transplanted scaffold in comparison to the mouse subretinal surface 
area. The RPCs are viable within the scaffold when transplanted and there is no invasion of host 
cells into the scaffold as evidenced by the presence of TRA1-85, a human antigen marker, seen on 
immunofluorescence within scaffold pores. 
There is RPC integration within the RD10 outer nuclear layer, which is the site of photoreceptor 
loss and injury, 6 weeks post transplantation when the RPC/GCH graft is transplanted. It is thought 
that RPCs migrate and home to the site of injury within the retina.  This integration is more notable 
when the RPCs on the scaffold are transplanted on D20-D24 of differentiation. During that 
timeline the cells are in the progenitor state and are more capable of differentiating into different 
retinal cells and integrating and further differentiating at the injury site.  
FACS analysis of RPCs was done on D50 of the differentiation protocol after transfection with 




only 2x105 Rho+ cells.20% of the RPC population was expressing rhodopsin which is present in 
the later stages of photoreceptor differentiation. 
The injection of 50,000 Rho+ cells in the subretinal space of RD10 mice resulted in a viable 
homogenous photoreceptor cluster in the subretinal space 3 weeks post injection. There was a few 
Ku-80+ cells, which is a human antigen marker, seen in the outer nuclear layer. However, it is 
unclear if these are the injected human cells which have migrated and integrated in the ONL or the 
remaining mouse photoreceptors have taken up the marker through cytoplasmic exchange (29). In 
that event, it would appear the transfer of mRNA to host cells had a protective effect. The 
transcleral injection of Rho+ cells causes minimal inflammation given there is only one IL-6 
positive cell detected at the injection site. The injection does not seem to have disrupted the retina 
blood barrier. Integration of rhodopsin expressing photoreceptors into the ONL might be more 
difficult, given these cells are almost mature photoreceptors. 
Cells in the RPC (differentiation day 20-24) stage can theoretically integrate more readily as 
evidenced in Fig. 12 in comparison to more mature RPCs this finding could be explained by the 
fact the retinal cups start forming during the D20-D24 timeframe and most of early eye field genes 
are expressed within this earlier window. It might be difficult for cells to migrate after complete 
commitment to a specific retinal lineage such as in the rhodopsin+ FACS sorted cells 
transplantation experiment. For this reason, the Rizzolo lab has acquired a GFP+ SIX6 expressing 
ESC line. SIX6 is an early eye field gene, and marks RPCs in an early differentiation stage. The 
SIX6+ stem cell population can be cell sorted and used to seed the GCH scaffold for further 
transplantation studies or subretinal injection studies. 
Retinal functional recovery evaluation post transplantation will be done using multifocal 




measurable functional recovery, it is hypothesized that at least 150,000 RPCs must integrate in the 
ONL layer in photoreceptor degenerative diseases (30). The lab is currently working on achieving 
a reliable method to perform mfERGs on the mouse models. 
 
Conclusions 
The GCH scaffold supported the differentiation and attachment of RPCs. The RPC/RPE co culture 
resulted in a polar planar retinal structure with recoverin expressing cells adjacent to the RPE layer.  
In this study, we found significant amount of cells migrated into the photoreceptor layers within 6 
weeks when RPC-GCH was implanted on differentiation days 20-24.  Less integration was seen 
when a homogenous photoreceptor population was injected in the subretinal space at a later 
differentiation time point. Furthermore, the scaffold was mostly degraded within the 6-week time 
frame without altering the retinal architecture or causing any immune rejection. However, there 
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Table 2- Antibody used for immunofluorescence 
Antibody         Type             Source          Dilution 
Sox2  Rabbit polyclonal Abcam  IF 1:100 
OTX2  Rabbit polyclonal  Novus Biologicals  IF 1:100 
PAX6  Rabbit polyclonal Abgent   IF 1:200 
LHX2  Goat polyclonal Santa Cruz Biotechnology   IF1:200 
CHX10/VSX2  Sheep monoclonal EMD Millipore   IF, 1:200 
RAX  Mouse monoclonal Abnova   IF, 1:500 
Rhodopsin  Rabbit  monoclonal Cell Signaling   IF, 1:300 
CRX  Rabbit polyclonal            Novus Biologicals   IF, 1:200   
β-Tubulin-III  Rabbit polyclonal Abcam   IF, 1:1500 
Ki67  Rabbit polyclonal Thermo Scientifics           IF,1:500 
CRX  Rabbit monoclonal Novus Biologicals  IF,1:200 
Recoverin   Rabbit polyclonal EMD Millipore  IF, 1:300 
TRA-1-85  Mouse monoclonal EMD Millipore  IF, 1:200 
IL-6  Mouse monoclonal Abcam  IF, 1:200 
IBA-1  Goat monoclonal Abcam  IF, 1:200 
 
Genes Forward Sequence 5’-3’ 
Reverse Sequence 3’-
5’                
Size 
(bp) 
            
BRN3 
 
CTC ACA CTG TCC CAC AAT AAT A 
 
CCG GCG GAA TAT TTC ATT CT 
311 
CHX10 ATT CAA CGA AGC CCA CTA CCC AGA ATC CTT GGC TGA CTT GAG GAT GGA 229 
CRX TAT TCT GTC AAC GCC TTG GCC CTA TGC ATT TAG CCC TCC GGT TCT TGA 253 
LHX2 CAA GAT CTC GGA CCG CTA CT CCG TGG TCA GCA TCT TGT TA 284 
NANOG CAA AGG CAA ACA ACC CAC TT TCT GCT GGA GGC TGA GGT AT 158 
NEUROD1 TAC TGC TGC AAA GTG CAA ATA C AAG TGC TAA GGC AAC ACA ATA AC 539 
OCT4 CGA GCA ATT TGC CAA GCT CCT GAA TTC GGG CAC TGC AGG AAC AAA TTC 324 
OTX2 CAA CAG CAG AAT GGA GGT CA CTG GGT GGA AAG AGA GAA GC TG 429 
PAX6 CGG AGT GAA TCA GCT CGG TG CCG CTT ATA CTG GGC TAT TTT GC   
300  
RAX GAA TCT CGA AAT CTC AGC CC CTT CAC TAA TTT GCT CAG GAC 279 
SIX3 CGA GCA GAA GAC GCA TTG CTT CAA CGG CCT TGG CTA TCA TAC ATC ACA 394 
SIX6 ATT TGG GAC GGC GAA CAG AAG ACA ATC CTG GAT GGG CAA CTC AGA TGT 385 
GAPDH TCACCAGGGCTGCTTTTAAC GACAAGCTTCCCGTTCTCAG 153 
